Holen Sie sich die Stockscreener-App
24.97
0.32%
0.08
Handel nachbörslich:
24.97
Schlusskurs vom Vortag:
$24.89
Offen:
$24.89
24-Stunden-Volumen:
179.30K
Relative Volume:
0.36
Marktkapitalisierung:
$1.10B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-166.31M
KGV:
-5.5984
EPS:
-4.4602
Netto-Cashflow:
$-160.59M
1W Leistung:
+18.85%
1M Leistung:
+6.57%
6M Leistung:
+25.16%
1J Leistung:
+52.07%
1-Tages-Spanne:
$24.89
$25.78
1-Wochen-Bereich:
$21.34
$25.78
52-Wochen-Spanne:
$15.47
$27.22
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
24.97 | 1.10B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2025-12-10 | Eingeleitet | BTIG Research | Buy |
| 2025-11-25 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-03-20 | Eingeleitet | B. Riley Securities | Buy |
| 2025-03-10 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet - Zacks Investment Research
Wall Street experts predict that ArriVent BioPharma, Inc. (AVBP) may climb by 72.44%. Check this out before making any investment decisions. - Bitget
ArriVent to present preclinical cancer drug data at AACR 2026 - MSN
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest - Yahoo Finance
AVBP Technical Analysis & Stock Price Forecast - Intellectia AI
Avoiding Lag: Real-Time Signals in (AVBP) Movement - Stock Traders Daily
Clear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
Gains Report: Whats next for ArriVent BioPharma Inc stock2026 Technicals & Weekly Breakout Stock Alerts - baoquankhu1.vn
Aug Highlights: How do insiders feel about ArriVent BioPharma IncAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 8.4%Here's Why - marketbeat.com
Aug Mood: Can ArriVent BioPharma Inc maintain sales growth2026 Investor Takeaways & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - marketbeat.com
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum Shift - Sahm
RONB Should I Buy - intellectia.ai
BCSM Should I Buy - intellectia.ai
GLND Should I Buy - Intellectia AI
DNMXU Should I Buy - Intellectia AI
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year? - Yahoo Finance
ArriVent BioPharma (NASDAQ:AVBP) Upgraded to Strong-Buy at Truist Financial - MarketBeat
MQY Should I Buy - Intellectia AI
VCX Should I Buy - Intellectia AI
Burkina Faso Integrates National Languages into AI Development Strategy - techafricanews.com
Weekly Investment Analysts’ Ratings Changes for ArriVent BioPharma (AVBP) - Defense World
ArriVent to Present Preclinical Cancer Drug Data at AACR 2026 - mychesco.com
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib (NASDAQ:AVBP) - Seeking Alpha
Discipline and Rules-Based Execution in AVBP Response - Stock Traders Daily
ArriVent BioPharma (NASDAQ:AVBP) Price Target Raised to $45.00 at B. Riley Financial - MarketBeat
B. Riley Securities Maintains Buy on ArriVent... - Benzinga
Arrivent Biopharma, Aveanna Healthcare Holdings, EQT - TradingView
Weekly Earnings: Is ArriVent BioPharma Inc subject to activist investor interest2026 Price Swings & Fast Moving Market Watchlists - baoquankhu1.vn
Is ArriVent BioPharma (AVBP) Offering Value After Recent Share Price Pullback? - Sahm
Is ArriVent BioPharma, Inc. (AVBP) stock outpacing its medical peers this year? - MSN
ArriVent BioPharma Unveils Promising Preclinical Data on Firmonertinib and Dual-Target ADC ARR-002 at 2026 AACR Annual Meeting - Minichart
ArriVent BioPharma (AVBP) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Truist Securities Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting - The Manila Times
Aarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026 - The National Law Review
ArriVent Highlights Next-Generation Oncology Data at AACR 2026 - TipRanks
ArriVent to present preclinical data on firmonertinib and dual-target ADC ARR-002 at AACR 2026 - TradingView
ArriVent BioPharma (AVBP) to showcase firmonertinib and ARR-002 preclinical data at AACR 2026 - Stock Titan
Lung and ovarian cancer drug data from ArriVent to debut at 2026 AACR - Stock Titan
Stock Report: What drives Assurant Incs stock price2026 Sentiment & Verified Entry Point Detection - baoquankhu1.vn
ArriVent BioPharma, Inc. $AVBP Shares Sold by Hidden Lake Asset Management LP - MarketBeat
Anson Funds Management LP Makes New Investment in ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma (AVBP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Suvretta Capital Management LLC Buys 290,664 Shares of ArriVent BioPharma, Inc. $AVBP - MarketBeat
ArriVent BioPharma (NASDAQ:AVBP) Upgraded at BTIG Research - MarketBeat
Wall Street analysts see a 70.37% upside in ArriVent BioPharma, Inc. (AVBP): Can the stock really move this high? - MSN
Behavioral Patterns of AVBP and Institutional Flows - Stock Traders Daily
ArriVent BioPharma's (AVBP) Buy Rating Reaffirmed at BTIG Research - MarketBeat
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):